April 24, 2018

Phase 2 ACCEPT Trial Explores Adding Acalabrutinib to Standard DLBCL Treatment

News

A Phase 2 clinical trial, ACCEPT, is designed to determine if adding acalabrutinib to standard, first-line R-CHOP chemotherapy will benefit patients with diffuse large B-cell lymphoma (DLBCL). The trial, ongoing ... Read more

June 28, 2017June 28, 2017

Tazemetostat Benefits Follicular and B-cell Lymphoma Patients with EZH2 Mutations, Phase 2 Trial Shows

News

Twelve of 13 patients with relapsed or refractory follicular lymphoma (FL) and mutations of the EZH2 enzyme responded either fully or partially to treatment with tazemetostat, according to a Phase 2 clinical trial. Tazemetostat, ... Read more